Talmage D. Egan
No Rating Available
(Learn About Our Rating System)

Talmage D. Egan, MD

Languages spoken: English, Japanese

Clinical Locations

University of Utah Hospital

Anesthesiology
Salt Lake City
801-581-6393

  • Dr. Egan completed his undergraduate education at Brigham Young University, graduating Magna Cum Laude in the humanities. He attended medical school at the University of Utah School of Medicine where he was inducted into the Alpha Omega Alpha academic honor society. After completing a preliminary general surgery residency at the University of Utah, Dr. Egan sought postgraduate training in anesthesiology and critical care which he completed at Stanford University. Following residency he pursued fellowship training in clinical pharmacology also at Stanford. He recently completed intensive physician executive training at the Harvard School of Public Health.

    Dr. Egan is currently staff physician and chair at the Department of Anesthesiology at the University of Utah Health Sciences Center. His clinical practice focuses on neurosurgery and obstetric patients. He is past President of the Medical Staff and Chairman of the Medical Board, and served for over a decade as the Chief of Neuroanesthesia.

    Dr. Egan's research interests include the clinical pharmacology of sedatives and analgesics, the development of novel intravenous anesthetics and alternative propofol formulations, the development of optimal drug administration regimens based on pharmacokinetic-pharmacodynamic concepts, the identification of factors (i.e., gender, body weight, shock, SNPs, etc.) that influence drug behavior, and computer controlled drug delivery technology. These interests have resulted in successful entrepreneurial ventures, patents and trademarks. Dr. Egan is internationally regarded as a pioneer in the development of total intravenous anesthesia techniques, particularly the clinical application of the short acting opioid remifentanil, and the characterization of the interaction between propofol and opioids. His publications have been accompanied by numerous editorials and have been featured as cover stories in leading, peer-reviewed anesthesiology journals. Dr. Egan has mentored over 20 junior faculty and graduate students who have emerged as independent investigators.

    Dr. Egan served for many years as a board member, treasurer, and president of the International Society for Anaesthetic Pharmacology. Currently an Associate Editor for the British Journal of Anaesthesia, he has also served as Associate Editor for Anesthesiology and guest reviewer for numerous other pharmacology, anesthesia and bioengineering journals. For many years Dr. Egan was a member and Chair of the American Society of Anesthesiology Subcommittee on Drug Disposition. He recently published a well-received anesthesia pharmacology and physiology textbook with Elsevier (Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application) as co-editor.

    Dr. Egan was the inaugural recipient of the International Anesthesia Research Society’s Teaching Recognition Award. He is holder of the K.C. Wong Presidential Endowed Chair in Anesthesiology at the University of Utah. Dr. Egan has lectured extensively in the United States and internationally, including numerous honorary and keynote lectures at major universities and international anesthesiology societies.

    His personal life is devoted to his wife of 30 years and their five children. He is fond of saying that his family is the most important element of his CV! Dr. Egan enjoys coaching basketball (two time Utah State AAU Boys Champions!), snow skiing, bass guitar, English literature and Japanese conversation.

    Specialties

    Board Certification

    American Board of Anesthesiology

  • Dr. Egan completed his undergraduate education at Brigham Young University, graduating Magna Cum Laude in the humanities. He attended medical school at the University of Utah School of Medicine where he was inducted into the Alpha Omega Alpha academic honor society. After completing a preliminary general surgery residency at the University of Utah, Dr. Egan sought postgraduate training in anesthesiology and critical care which he completed at Stanford University. Following residency he pursued fellowship training in clinical pharmacology also at Stanford. He recently completed intensive physician executive training at the Harvard School of Public Health.

    Dr. Egan is currently staff physician and chair at the Department of Anesthesiology at the University of Utah Health Sciences Center. His clinical practice focuses on neurosurgery and obstetric patients. He is past President of the Medical Staff and Chairman of the Medical Board, and served for over a decade as the Chief of Neuroanesthesia.

    Dr. Egan's research interests include the clinical pharmacology of sedatives and analgesics, the development of novel intravenous anesthetics and alternative propofol formulations, the development of optimal drug administration regimens based on pharmacokinetic-pharmacodynamic concepts, the identification of factors (i.e., gender, body weight, shock, SNPs, etc.) that influence drug behavior, and computer controlled drug delivery technology. These interests have resulted in successful entrepreneurial ventures, patents and trademarks. Dr. Egan is internationally regarded as a pioneer in the development of total intravenous anesthesia techniques, particularly the clinical application of the short acting opioid remifentanil, and the characterization of the interaction between propofol and opioids. His publications have been accompanied by numerous editorials and have been featured as cover stories in leading, peer-reviewed anesthesiology journals. Dr. Egan has mentored over 20 junior faculty and graduate students who have emerged as independent investigators.

    Dr. Egan served for many years as a board member, treasurer, and president of the International Society for Anaesthetic Pharmacology. Currently an Associate Editor for the British Journal of Anaesthesia, he has also served as Associate Editor for Anesthesiology and guest reviewer for numerous other pharmacology, anesthesia and bioengineering journals. For many years Dr. Egan was a member and Chair of the American Society of Anesthesiology Subcommittee on Drug Disposition. He recently published a well-received anesthesia pharmacology and physiology textbook with Elsevier (Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application) as co-editor.

    Dr. Egan was the inaugural recipient of the International Anesthesia Research Society’s Teaching Recognition Award. He is holder of the K.C. Wong Presidential Endowed Chair in Anesthesiology at the University of Utah. Dr. Egan has lectured extensively in the United States and internationally, including numerous honorary and keynote lectures at major universities and international anesthesiology societies.

    His personal life is devoted to his wife of 30 years and their five children. He is fond of saying that his family is the most important element of his CV! Dr. Egan enjoys coaching basketball (two time Utah State AAU Boys Champions!), snow skiing, bass guitar, English literature and Japanese conversation.

    Board Certification and Academic Information

    Academic Departments Anesthesiology -Primary
    Neurosurgery -Adjunct
    Board Certification
    American Board of Anesthesiology

    Education history

    Fellowship Pharmacology - Stanford University School of Medicine Fellow
    Residency Anesthesiology - Stanford University Medical Center Resident
    Residency Anesthesiology - University of Utah School of Medicine Resident
    Residency Surgery - University of Utah School of Medicine Resident
    Internship Surgery - University of Utah School of Medicine Intern
    Professional Medical Medicine - University of Utah M.D.
    Undergraduate Humanities - Brigham Young University B.A.

    Selected Publications

    Journal Article

    1. Ermer S, Brewer L, Orr J, Egan TD, Johnson K (2018). Comparison of 7 Different Sensors for Detecting Low Respiratory Rates Using a Single Breath Detection Algorithm in Nonintubated, Sedated Volunteers. Anesth Analg, 129(2), 399-408. (Read full article)
    2. Egan TD (2019). Are opioids indispensable for general anaesthesia? Br J Anaesth, 122(6), e127-e135. (Read full article)
    3. Kim TK, Obara S, Egan TD, Minto CF, La Colla L, Drover DR, Vuyk J, Mertens M, the Remifentanil Pharmacokinetics in Obesity Investigators (2017). Disposition of Remifentanil in Obesity: A New Pharmacokinetic Model Incorporating the Influence of Body Mass. Anesthesiology, 126(6), 1019-1032. (Read full article)
    4. Kim TK, Obara S, Egan TD, Minto CF, La Colla L, Drover DR, Vuyk J, Mertens M (01/01/2017). Disposition of Remifentanil in Obesity: A New Pharmacokinetic Model Incorporating the Influence of Body Mass. Anesthesiology, 126(6), 1019-1032.
    5. Soto R, Jahr JS, Pavlin J, Sabo D, Philip BK, Egan TD, Rowe E, de Bie J, Woo T (2015). Safety and Efficacy of Rocuronium With Sugammadex Reversal Versus Succinylcholine in Outpatient Surgery-A Multicenter, Randomized, Safety Assessor-Blinded Trial. Am J Ther, 23(6), e1654-e1662. (Read full article)
    6. Shafer SL, Egan T (2016). Target-Controlled Infusions: Surfing USA Redux. Anesth Analg, 122(1), 1-3.
    7. Kim TK, Niklewski PJ, Martin JF, Obara S, Egan TD (2015). Enhancing a sedation score to include truly noxious stimulation: the Extended Observer's Assessment of Alertness and Sedation (EOAA/S). Br J Anaesth, 115(4), 569-77. (Read full article)
    8. Sear JW, Egan TD (2015). David (Propofol Wannabes) Versus Goliath (Propofol): AZD-3043 Goes Up Against the Giant! Anesth Analg, 121(4), 849-51.
    9. Egan TD (2015). Total intravenous anesthesia versus inhalation anesthesia: a drug delivery perspective. J Cardiothorac Vasc Anesth, 29 Suppl 1, S3-6. (Read full article)
    10. Egan, TD (2015). Total intravenous anesthesia versus inhalation anesthesia: a drug delivery perspective. J Cardiothorac Vasc Anesth, 29(Suppl 1), S3-6.
    11. Egan, TD (2015). Update on total intravenous anesthesia with special emphasis on cardiovascular anesthesia. J Cardiothorac Vasc Anesth, 29(Suppl 1), S1-2.
    12. Yu L, Ting CK, Hill BE, Orr JA, Brewer LM, Johnson KB, Egan TD, Westenskow DR (2013). Using the entropy of tracheal sounds to detect apnea during sedation in healthy nonobese volunteers. Anesthesiology, 118(6), 1341-9. (Read full article)
    13. Hanrahan SJ, Greger B, Parker RA, Ogura T, Obara S, Egan TD, House PA (2013). The effects of propofol on local field potential spectra, action potential firing rate, and their temporal relationship in humans and felines. Front Hum Neurosci, 7, 136. (Read full article)
    14. Syroid N, Liu D, Albert R, Agutter J, Egan TD, Pace NL, Johnson KB, Dowdle MR, Pulsipher D, Westenskow DR (2012). Graphical user interface simplifies infusion pump programming and enhances the ability to detect pump-related faults. Anesth Analg, 115(5), 1087-97. (Read full article)
    15. LaPierre CD, Johnson KB, Randall BR, Egan TD (2012). A simulation study of common propofol and propofol-opioid dosing regimens for upper endoscopy: implications on the time course of recovery. Anesthesiology, 117(2), 252-62. (Read full article)
    16. Egan TD, Obara S, Jenkins TE, Jaw-Tsai SS, Amagasu S, Cook DR, Steffensen SC, Beattie DT (2012). AZD-3043: a novel, metabolically labile sedative-hypnotic agent with rapid and predictable emergence from hypnosis. Anesthesiology, 116(6), 1267-77. (Read full article)
    17. Wallentine CB, Shimode N, Egan TD, Pace NL (2011). Propofol in a modified cyclodextrin formulation: first human study of dose-response with emphasis on injection pain. Anesth Analg, 113(4), 738-41. (Read full article)
    18. Crystal B Wallentine, MD, Noriko Shimode, MD, Talmage D Egan, MD, and Nathan Pace, MD, MStat (October 2011). Propofol in a Modified Cyclodextrin Formulation: First Human Study of Dose-Response with Emphasis on Injection Pain. Anesth Analg, 113(4), 738-741.
    19. LaPierre CD, Johnson KB, Randall BR, White JL, Egan TD (2011). An exploration of remifentanil-propofol combinations that lead to a loss of response to esophageal instrumentation, a loss of responsiveness, and/or onset of intolerable ventilatory depression. Anesth Analg, 113(3), 490-9. (Read full article)
    20. Johnson KB, Syroid ND, Gupta DK, Manyam SC, Pace NL, LaPierre CD, Egan TD, White JL, Tyler D, Westenskow DR (2010). An evaluation of remifentanil-sevoflurane response surface models in patients emerging from anesthesia: model improvement using effect-site sevoflurane concentrations. Anesth Analg, 111(2), 387-94. (Read full article)
    21. Syroid ND, Johnson KB, Pace NL, Westenskow DR, Tyler D, Brhschwein F, Albert RW, Roalstad S, Costy-Bennett S, Egan TD (2010). Response surface model predictions of emergence and response to pain in the recovery room: An evaluation of patients emerging from an isoflurane and fentanyl anesthetic. Anesth Analg, 111(2), 380-6. (Read full article)
    22. Sakata DJ, Matsubara I, Gopalakrishnan NA, Westenskow DR, White JL, Yamamori S, Egan TD, Pace NL (2009). Flow-through versus sidestream capnometry for detection of end tidal carbon dioxide in the sedated patient. J Clin Monit Comput, 23(2), 115-22. (Read full article)
    23. Johnson KB, Syroid ND, Gupta DK, Manyam SC, Egan TD, Huntington J, White JL, Tyler D, Westenskow DR (2008). An evaluation of remifentanil propofol response surfaces for loss of responsiveness, loss of response to surrogates of painful stimuli and laryngoscopy in patients undergoing elective surgery. Anesth Analg, 106(2), 471-9, table of contents. (Read full article)
    24. Stanley TH, Egan TD, Van Aken H (2008). A tribute to Dr. Paul A. J. Janssen: entrepreneur extraordinaire, innovative scientist, and significant contributor to anesthesiology. Anesth Analg, 106(2), 451-62, table of contents. (Read full article)
    25. Manyam SC, Gupta DK, Johnson KB, White JL, Pace NL, Westenskow DR, Egan TD (2007). When is a bispectral index of 60 too low?: Rational processed electroencephalographic targets are dependent on the sedative-opioid ratio. Anesthesiology, 106(3), 472-83. (Read full article)
    26. Nelson RY, Bretz B, Egan TD (2007). Prolonged apnea after remifentanil. J Clin Anesth, 19, 60-63.
    27. Manyam SC, Gupta DK, Johnson KB, White JL, Pace NL, Westenskow DR, Egan TD (2006). Opioid-volatile anesthetic synergy: a response surface model with remifentanil and sevoflurane as prototypes. Anesthesiology, 105(2), 267-78. (Read full article)
    28. Sikharam S, Egan TD, Kern SE (2005). Cyclodextrins as new formulation entities and therapeutic agents. Curr Opin Anaesthesiol, 18(4), 392-5. (Read full article)
    29. Davis JJ, Swenson JD, Hall RH, Dillon JD, Johnson KB, Egan TD, Pace NL, Niu SY (2005). Preoperative "fentanyl challenge" as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients. Anesth Analg, 101(2), 389-95, table of contents. (Read full article)
    30. Richardson SP, Egan TD (2005). The safety of remifentanil by bolus injection. Expert Opin Drug Saf, 4(4), 643-51. (Read full article)
    31. Johnson KB, Egan TD, Kern SE, McJames SW, Cluff ML, Pace NL (2004). Influence of hemorrhagic shock followed by crystalloid resuscitation on propofol: a pharmacokinetic and pharmacodynamic analysis. Anesthesiology, 101(3), 647-59. (Read full article)
    32. Kern SE, Xie G, White JL, Egan TD (2004). A response surface analysis of propofol-remifentanil pharmacodynamic interaction in volunteers. Anesthesiology, 100(6), 1373-81. (Read full article)
    33. Coull JT, Jones ME, Egan TD, Frith CD, Maze M (2004). Attentional effects of noradrenaline vary with arousal level: selective activation of thalamic pulvinar in humans. Neuroimage, 22(1), 315-22. (Read full article)
    34. Egan TD, Kern SE, Muir KT, White J (2004). Remifentanil by bolus injection: a safety, pharmacokinetic, pharmacodynamic, and age effect investigation in human volunteers. Br J Anaesth, 92(3), 335-43. (Read full article)
    35. Davis JJ, Johnson KB, Egan TD, Vezina DP, Snell TE, Swenson JD (2003). Preoperative fentanyl infusion with pharmacokinetic simulation for anesthetic and perioperative management of an opioid-tolerant patient. Anesth Analg, 97(6), 1661-2. (Read full article)
    36. Egan TD (2003). Target-controlled drug delivery: progress toward an intravenous "vaporizer" and automated anesthetic administration. Anesthesiology, 99(5), 1214-9. (Read full article)
    37. Lee M, Kern SE, Kisicki JC, Egan TD (2003). A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate. J Pain Symptom Manage, 26(2), 743-7. (Read full article)
    38. Johnson KB, Egan TD, Kern SE, White JL, McJames SW, Syroid N, Whiddon D, Church T (2003). The influence of hemorrhagic shock on propofol: a pharmacokinetic and pharmacodynamic analysis. Anesthesiology, 99(2), 409-20. (Read full article)
    39. Egan TD, Kern SE, Johnson KB, Pace NL (2003). The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model. Anesth Analg, 97(1), 72-9, table of contents. (Read full article)
    40. Johnson KB, Egan TD, Layman J, Kern SE, White JL, McJames SW (2003). The influence of hemorrhagic shock on etomidate: a pharmacokinetic and pharmacodynamic analysis. Anesth Analg, 96(5), 1360-8, table of contents. (Read full article)
    41. Davis PJ, Stiller RL, Wilson AS, McGowan FX, Egan TD, Muir KT (2002). In vitro remifentanil metabolism: the effects of whole blood constituents and plasma butyrylcholinesterase. Anesth Analg, 95(5), 1305-7, table of contents. (Read full article)
    42. Johnson KB, Swenson JD, Egan TD, Jarrett R, Johnson M (2002). Midazolam and remifentanil by bolus injection for intensely stimulating procedures of brief duration: experience with awake laryngoscopy. Anesth Analg, 94(5), 1241-3, table of contents. (Read full article)
    43. Barr J, Egan TD, Sandoval NF, Zomorodi K, Cohane C, Gambus PL, Shafer SL (2001). Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. Anesthesiology, 95(2), 324-33. (Read full article)
    44. Johnson KB, Kern SE, Hamber EA, McJames SW, Kohnstamm KM, Egan TD (2001). Influence of hemorrhagic shock on remifentanil: a pharmacokinetic and pharmacodynamic analysis. Anesthesiology, 94(2), 322-32. (Read full article)
    45. Egan TD, Muir KT, Hermann DJ, Stanski DR, Shafer SL (2001). The EEG and clinical measures of opioid potency: defining the EEG-clinical potency relationship ('fingerprint') with application to remifentanil. 15, 11-19.
    46. Egan TD (2000). Pharmacokinetics and pharmacodynamics of remifentanil: an update in the year 2000. Curr Opin Anaesthesiol, 13(4), 449-55. (Read full article)
    47. Manullang TR, Chun K, Egan TD (2000). The use of remifentanil for Cesarean section in a parturient with recurrent aortic coarctation. Can J Anaesth, 47(5), 454-9. (Read full article)
    48. Miner JE, Egan TD (2000). An AIDS-associated cause of the difficult airway: supraglottic Kaposi's sarcoma. Anesth Analg, 90(5), 1223-6. (Read full article)
    49. Egan TD, Sharma A, Ashburn MA, Kievit J, Pace NL, Streisand JB (2000). Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. Anesthesiology, 92(3), 665-73. (Read full article)
    50. Farnsworth ST, Egan TD, Johnson SE, Westenskow D (2000). Teaching sedation and analgesia with simulation. J Clin Monit Comput, 16(4), 273-85. (Read full article)
    51. Manullang J, Egan TD (1999). Remifentanil's effect is not prolonged in a patient with pseudocholinesterase deficiency. Anesth Analg, 89(2), 529-30. (Read full article)
    52. Egan TD, Kuramkote S, Gong G, Zhang J, McJames SW, Bailey PL (1999). Fentanyl pharmacokinetics in hemorrhagic shock: a porcine model. Anesthesiology, 91(1), 156-66. (Read full article)
    53. Hermann DJ, Egan TD, Muir KT (1999). Influence of arteriovenous sampling on remifentanil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther, 65(5), 511-8. (Read full article)
    54. Reusche MD, Egan TD (1999). Remifentanil for conscious sedation and analgesia during awake fiberoptic tracheal intubation: a case report with pharmacokinetic simulations. J Clin Anesth, 11(1), 64-8. (Read full article)
    55. Smyth E, Egan TD (1998). Apneic oxygenation associated with patient-controlled analgesia. J Clin Anesth, 10(6), 499-501. (Read full article)
    56. Egan TD, Huizinga B, Gupta SK, Jaarsma RL, Sperry RJ, Yee JB, Muir KT (1998). Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology, 89(3), 562-73. (Read full article)
    57. Brada SA, Egan TD, Viscomi CM (1998). The use of remifentanil infusion to facilitate epidural catheter placement in a parturient: a case report with pharmacokinetic simulations. Int J Obstet Anesth, 7(2), 124-7. (Read full article)
    58. Streisand JB, Busch MA, Egan TD, Smith BG, Gay M, Pace NL (1998). Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology, 88(2), 305-9. (Read full article)
    59. Egan TD (1998). The clinical pharmacology of remifentanil: a brief review. J Anesth, 12, 195-204.
    60. Johnson KB, Egan TD (1998). Remifentanil and propofol combination for awake craniotomy: case report with pharmacokinetic simulations. J Neurosurg Anesthesiol, 10(1), 25-9. (Read full article)
    61. Egan TD (1997). Remifentanil: an esterase-metabolized opioid. West J Med, 166(3), 202. (Read full article)
    62. Egan TD (1997). The clinical pharmacology of the new fentanyl congeners. Anesth Analg.
    63. Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Gambus PL, Billard V, Hoke JF, Moore KH, Hermann DJ, Muir KT, Mandema JW, Shafer SL (1997). Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology, 86(1), 10-23. (Read full article)
    64. Egan TD (1996). Intravenous drug delivery systems: toward an intravenous "vaporizer". J Clin Anesth, 8(3 Suppl), 8S-14S. (Read full article)
    65. Egan TD, Minto CF, Hermann DJ, Barr J, Muir KT, Shafer SL (1996). Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology, 84(4), 821-33. (Read full article)

    Review

    1. Egan TD (1998). The clinical pharmacology of remifentanil: a brief review. [Review]. J Anesth, 12(4), 195-204. (Read full article)

    Book

    1. Hemmings HC, Egan TD (2013). Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application. Elselvier Inc.
    2. Egan TD, Stanley TH (1999). Anesthesia for the New Millenium: Modern Anesthetic Clinical Pharmacology. Dordrecht, Holland: Kluwer Academic Publishers.

    Book Chapter

    1. Egan TD, Newberry C (01/01/2018). Opioids. In Miller RD, Pardo MC (Eds.), Basics of Anesthesia (7th). Philadelphia, PA: Elsevier.
    2. Thackeray E, Egan, TD (2015). Analgesics. In Barash PG, Cullen BF, Stoelting RK, Cahalan MK, Stock MC, Ortega R, Sharar SR (Eds.), Clincal Anesthesia Fundamentals. New Haven: Wolters Kluwer Health Aids.
    3. Thackeray EM, Egan TD (01/01/2015). Analgesics. In Barash PG, Cullen BF, Stoelting RK, Cahalan MK, Stock MC, Ortega R, Sharar SR (Eds.), Clinical Anesthesia Fundamentals (1st). Philadelphia, PA: Wolters Kluwer Health.
    4. Johnson KB, Egan TD (01/01/2015). Blood loss: Does it change my intravenous anesthetic? In Smith CE, Como J (Eds.), Trauma Anesthesia (2nd). New York, NY: Cambridge University Press.
    5. Obara S, Egan TD (2013). Pharmacokinetic and Pharmacodynamic Principles for Intravenous Anesthetics. In Hemmings HC, Egan TD (Eds.), Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application. Elsevier Inc.
    6. Ogura T, Egan TD (2013). Opioid Agonists and Antagonists. In Hemmings HC, Egan TD (Eds.), Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application (pp. 253-271). Elsevier.
    7. Johnson KB, Egan TD (2008). Blood loss: does it change my intravenous anesthetic? In Smith CE, Como J (Eds.), Trauma Anesthesia. New York, NY: Cambridge University Press.
    8. Johnson KB, Egan TD (2008). Principles of pharmacokinetics and pharmacodynamics: applied clinical pharmacology for the practitioner. In Longnecker DE, Brown DL, Newman MF, and Zapol WM (Eds.), Anesthesiology. New York, NY: McGraw Hill.
    9. Loose E, Egan TD (2006). Short Acting Intravenous Anesthetics. In Springman SR (Ed.), Ambulatory Anesthesia. Philadelphia, PA: Mosby/Elsevier.
    10. Egan TD, Minto CF (2003). Pharmacodynamic drug interactions in anesthetic practice. In Evers AS, Maze M (Eds.), Anesthetic Pharmacology: Physiologic Principles and Clinical Practice. Philadelphia: Churchill Livingstone.
    11. Egan TD, Wong KC (2001). Cigarette Smoking Cessation and Anesthesia. In M Roizen, L Fleisher (Eds.), Essence of Anesthesia Practice (2nd Edition). Orlando, FL: WB Saunders Company.
    12. Egan TD (2001). Anesthetic considerations for awake craniotomy: a practical approach. In Johnson JO, Stanley TH (Eds.), A Neuroanesthesia Odyssey. Salt Lake City, UT: University of Utah Press.
    13. Egan TD (2001). The processed eletroencephalogram in clinical anesthesiology with special reference to the clinical application of the bisectral index. In Johnson JO, Stanley TH (Eds.), A Neuroanesthesia Odyssey. Salt Lake City, UT: University of Utah Press.
    14. Egan TD (1999). Remifentanil: clinical applications. In Egan TD, Stanley TH (Eds.), Anesthesia for the New Millennium- Modern Anesthetic Clinical Pharmacology. Dordrecht, The Netherlands: Kluwer Academic Publishers.
    15. Egan TD (1999). Handedness in anesthetic pharmacology. In Egan TD, Stanley TH (Eds.), Anesthesia for the New Millennium- Modern Anesthetic Clinical Pharmacology. Dordrecht, The Netherlands: Kluwer Academic Publishers.
    16. Ladd AL, Egan TD, Swenson JD (1999). Shoulder Surgery. In R Jaffe, S Samuels (Eds.), Anesthesiologist's Manual of Surgical Procedures (2nd Edition). New York, NY: Raven Press.
    17. Brody GA, Rinsky LA, Egan TD, Swenson JD (1999). Hand Surgery. In R Jaffe, S Samuels (Eds.), Anesthesiologist's Manual of Surgical Procedures (2nd Edition). New York, NY: Raven Press.
    18. Bailey PL, Egan TD, Stanley TH (1999). Opioids. In RD Miller (Ed.), Anesthesia (5th Edition). New York, NY: Churchill Livingstone.
    19. Egan TD (1998). Modern clinical pharmacology concepts and pain management. In MA Ashburn, LJ Rice (Eds.), The Management of Pain (1st Edition). New York, NY: Churchill Livinstone.
    20. Egan TD (1997). Intravenous Drug Delivery Devices and Computer Control. In P White (Ed.), Intravenous Anesthesia and Analgesia (2nd Edition). Philadelphia, PA: Lea and Febiger.
    21. Bailey PL, Egan TD (1997). Fentanyl and Congeners. In P White (Ed.), Intravenous Anesthesia and Analgesia (2nd Edition). Philadelphia, PA: Lea and Febiger.
    22. Egan TD, Wong KC (1996). Cigarette Smoking Cessation and Anesthesia. In M Roizen, L Fleisher (Eds.), Essence of Anesthesia Practice (1st Edition). Orlando, FL: WB Saunders Company.

    Case Report

    1. Nelson RY, Bretz B, Egan TD (2007). Prolonged apnea after remifentanil. J Clin Anesth, 19(1), 60-3. (Read full article)
    2. Honan DM, Breen PJ, Boylan JF, McDonald NJ, Egan TD (2002). Decrease in bispectral index preceding intraoperative hemodynamic crisis: evidence of acute alteration of propofol pharmacokinetics. Anesthesiology, 97(5), 1303-5. (Read full article)

    Editorial

    1. Egan TD, Svensen CH (2018). Multimodal General Anesthesia: A Principled Approach to Producing the Drug-Induced, Reversible Coma of Anesthesia. Anesth Analg, 127(5), 1104-1106. (Read full article)
    2. Egan TD (2018). An Intellectual Framework for Drug Administration Methods in Anesthesia: Three Practice Domains. Anesth Analg, 127(4), 817-819. (Read full article)
    3. Short TG, Campbell D, Egan TD (2018). Increasing the utility of target-controlled infusions: one model to rule them all. Br J Anaesth, 120(5), 887-890. (Read full article)
    4. Short TG, Campbell D, Egan TD (01/01/2018). Increasing the utility of target-controlled infusions: one model to rule them all. B Jr Anesth, 120(5), 887-890.
    5. Kuck K, Egan TD (2017). Getting the dose right: anaesthetic drug delivery and the posological sweet spot. Br J Anaesth, 119(5), 862-864. (Read full article)
    6. Kuck K, Egan TD (01/01/2017). Getting the dose right: anaesthetic drug delivery and the posological sweet spot. Br J Anesth, 119(5), 862-864.
    7. Shafer SL, Egan TD (01/01/2016). Target-controlled infusions: surfing USA redux. Anesth Analg, 122(1), 1-3.
    8. Sear JW, Egan TD (2015). David (Propofol Wannabes) Versus Goliath (Propofol): AZD-3043 Goes Up Against the Giant! Anesth Analg, 121(4), 849-51. (Read full article)
    9. Egan TD (2015). Update on total intravenous anesthesia with special emphasis on cardiovascular anesthesia. J Cardiothorac Vasc Anesth, 29 Suppl 1, S1-2. (Read full article)
    10. Egan, TD (01/01/2015). Update on total intravenous anesthesia with special emphasis on cardiovascular anesthesia. J Cardiothorac Vasc Anesth, 29(Suppl 1), S1-2.
    11. Egan TD (2010). Exploring the frontiers of propofol formulation strategy: is there life beyond the milky way? Br J Anaesth, 104(5), 533-5. (Read full article)
    12. Egan TD (2009). Is anesthesiology going soft?: trends in fragile pharmacology. Anesthesiology, 111(2), 229-30. (Read full article)
    13. Gupta DK, Manyam SC, Johnson KB, Egan TD (2007). Can 1% of sevoflurane with 5 ng/ml of remifentanil prevent implicit memory? Anesthesiology, 107, 1031.
    14. Egan TD, Shafer SL (2003). Target-controlled infusions for intravenous anesthetics: surfing USA not! Anesthesiology, 99(5), 1039-41. (Read full article)
    15. Egan TD (1996). Stereochemistry and anesthetic pharmacology: joining hands with the medicinal chemists. Anesth Analg, 83(3), 447-50. (Read full article)

    Letter

    1. Taikawa D, Soto E, Kurosaki D, Hiraoka H, Horiuchi R, Goto F, Johnson KB, Egan TD (2005). Pharmacodynamics of propofol during hemorrhagic shock [Letter to the editor]. Anesthesiology, 102(5), 1068-1070.
    2. Egan TD, Kern SE (2004). Remifentanil is too potent to be given by bolus. [Letter to the editor]. Br J Anaesth, 93(2), 305-306.
    3. Egan TD (1998). New horizons in IV anesthesia. Society for Intravenous Anesthesia Newsletter [Letter to the editor]. Anesth Analg, 3 (1), 2.
    4. Bailey PL, Egan TD (1997). The successful implementation of pharmaceutical practice guidelines? Far from convincing! [Letter to the editor]. Anesthesiology, 87(6), 1583-4. (Read full article)

    Abstract

    1. Ermer S, Brewer L, Orr JA, Egan TD, Johnson KB (01/12/2018). Comparison of a Wide Respiratory Rate Range Reported from Seven Sensors in Non- Intubated, Spontaneously Breathing Volunteers [Abstract]. Society for Technology in Anesthesia Annual Meeting, Miami, FL, January 12, 2018.
    2. Brewer L, Enos JS, Orr JA, Egan TD, Johnson KB (10/21/2017). A Computerized System to Prompt Healthy Volunteers to Breathe During Drug-Induced Respiratory Depression [Abstract]. American Society of Anesthesiologists Annual Meeting, Boston, MA, October 21, 2017.
    3. Ermer S, Johnson KB, Orr JA, Hoehne S, White J, Egan TD, Brewer L (01/08/2016). Analysis of Central and Obstructive Apnea Detection Using Combination Sensors [Abstract]. Society for Technology in Anesthesia Annual Meeting, Palm Beach, FL, January 8, 2016.
    4. Gupta DK, Manyam SC, Johnson KB, White JL, Egan TD (2003). The Auditory Evoked Potential and the Bispectral Index: A Comparison of Signal Performance During Clinically Inadequate Anesthesia [Abstract]. Anesthesiology, 99, A328.
    5. Sakaguchi FH, Syroid ND, White JB, Tyler DL, Egan TD (2003). Applying a Propofol-Remifentanil Response Surface Interaction Model in the Operating Room: An Observational Study [Abstract]. Anesthesiology, 99, A495.
    6. Johnson KB, Egan TD, McJames SW, Cluff ML, Kern SE (2003). The Influence of Hemorrhagic Shock Followed by Crystalloid Resuscitation on Propofol: A Pharmacokinetic Analysis [Abstract]. Anesthesiology, 99, A652.
    7. Egan TD, Shafer SL, Jenkins TE, Beattie DT, Jaw-Tsai SS (2003). The Pharmacokinetics and Pharmacodynamics of THRX-918661, a Novel Sedative/Hypnotic Agent [Abstract]. Anesthesiology, 99, A516.
    8. Manyam SC, Chatwin DM, Decou JA, Johnson KB, White TD, Egan TD (2003). The auditory evoked potential and the bispectral index: A comparison study examining signal responses to inadequate anesthesia [Abstract]. Anesth Analg, 96, S132.
    9. Mazer NA, Zobrist H, Stanworth SH, Egan TD (2002). Oral transmucosal administration of fentanyl acutely lowers LH and testosterone levels in healthy young men [Abstract]. Proceedings of the 84th Annual Meeting of the Endocrine Society, Poster #P2-666, San Francisco, CA.
    10. Egan TD, Kern SE, Johnson KB, Pace NL (2002). The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model [Abstract]. Anesthesiology, 97, A437.
    11. Johnson KB, Peterson G, Egan TD, Kern SE, Pace NL (2002). Does propofol influence its own pharmacokinetics? A look at short duration high does propofol infusions in swine [Abstract]. Anesthesiology, 97, A681.
    12. Jones M, Coull J, Egan T, Maze M (2001). Are subjects more easily aroused during sedation with the alpha-2 agonist dexmedetomidine? [Abstract]. Br J Anaesth, 86, 324P.
    13. Egan TD, Kern SE, Roland CL, Gay M (2001). The pharmacokinetics and safety of oral transmucosal fentanyl administered to healthy volunteers as two 400 mcg dosage units or as a single 800 mcg Actiq dosage unit [Abstract]. Proceedings of the 2001 Annual Meeting of the American Pain Society.
    14. Egan TD, Kern SE, Johnson KB, Pace NL (2001). The Pharmacodynamics of propofol in a modified cyclodextrin formulation versus propofol in an intralipid formulation: an electroencephalographic and hemodynamic study in a porcine model [Abstract]. Anesthesiology, 95, A490.
    15. Johnson KB, Egan TD, Kern SE, Whiddon D, Lee J (2001). The influence of hemorrhagic shock on propofol: a pharmacokinetic analysis [Abstract]. Anesthesiology, 95, A649.
    16. Lertratanakul A, Kern SE, Egan TD (2001). EEG Approximate Entropy for Assessment of Subject Responsiveness to Laryngoscopy [Abstract]. Anesthesiology, 95, A292.
    17. Kern SE, Linares OJ, Egan TD (2000). Non-linear indicators of electroencephalographic changes that correlate with changing anesthetic concentrations [Abstract]. Anesthesiology, 93, A1372.
    18. Kern SE, Roland C, White JL, Gay MA, Egan TD (2000). PK/PD Analysis of etomidate given across the buccal mucosa [Abstract]. Anesthesiology, 93, A532.
    19. Egan TD, Roland C, White JL, Gay MA, Kern SE (2000). A pilot study of oral transmucosal etomidate in volunteers [Abstract]. Anesthesiology, 93, A519.
    20. Egan TD, Kern SE, White JL, Cluff M (2000). Characterizing pharmacodynamic synergism between propofol and remifentanil in volunteers using response surfaces [Abstract]. Proceedings of the 2000 Annual Meeting of the Association of University Anesthetists.
    21. Kern SE, Dezaire DPJ, White JL, Egan TD (1999). Assessing the facial EMB as an indicator of response to noxious stimuli in anesthetized volunteers [Abstract]. Anesthesiology, 91, A594.
    22. Kern SE, Egan TD, White JL, Cluff M (1999). Characterizing pharmacodynamic synergism between propofol and remifentanil in volunteers using response surfaces [Abstract]. Anesthesiology, 91, A342.
    23. Johnson KJ, Kern SE, Egan TD (1999). The effect of hypnotic-opioid interaction on target controlled infusion performance [Abstract]. Anesthesiology, 91, A343.
    24. Egan TD, Kern SE, White JL (1999). Prospective pharmacokinetic and pharmacodynamic validation on propofol's context sensitive T 1/2 [Abstract]. Anesthesiology, 91, A347.
    25. White JL, Kern SE, Egan TD (1999). Analgesia and respiratory effects of remifentanil boluses in elderly and adult volunteers [Abstract]. Anesthesiology, 91, A14.
    26. Egan TD, Kern SE, White JL, Wells DL, Johnson JO (1998). Assessing hypnotic and opioid interactions in volunteers using surrogate measures: a new study paradigm [Abstract]. Anesthesiology, A483.
    27. Kern SE, Johnson KB, Hamber EA, McJames S, Gong G, Kohnstamm K, Egan TD (1998). The influence of hemorrhagic shock on remifentanil: a pharmacodynamic analysis [Abstract]. Anesthesiology, A523.
    28. Johnson KB, Kern SE, Hamber EA, McJames S, Gong G, Kohnstamm K, Egan TD (1998). The influence of hemorrhagic shock on remifentanil: a pharmacokinetic analysis [Abstract]. Anesthesiology, A524.
    29. Lu J, Kern S, Schafer S, Bailey PL, Egan TD (1997). Prospective pharmacokinetic and pharmacodynamic validation of the context sensitive half-time for alfentanil [Abstract]. Anesthesiology, 87, A347.
    30. Kuramkote S, Egan TD, McJames S, Gong G, Bailey PL (1997). Hemorrhagic shock alters fentanyl pharmacokinetics [Abstract]. Anesthesiology, 87, A374.
    31. Egan TD, Muir KT, Stanski DR, Shafer SL (1996). The EEG versus clinical measures of opioid potency: defining the EEG-clinical potency fingerprint with application to remifentanil [Abstract]. Anesthesiology, 85, A349.
    32. Egan TD, Muir KT, Stanski DR, Shafer SL (1996). Using the EEG fingerprint to define the clinical pharmacology of a new opioid: application to remifentanil [Abstract]. Clin Pharmacol Ther, 59, 129.
    33. Egan TD, Gupta SK, Sperry RJ, Yee JB, Huizinga B, Jaarsma RL, Muir KT (1996). The pharmacokinetics of remifentanil in obese versus lean elective surgery patients [Abstract]. Anesth Analg, 82, S100.

    Video/Film/CD/Web/Podcast

    1. Egan TD, Syroid N, Agutter J, Johnson KB (07/01/2018). Safe Sedation Training for Moderate Sedation (SSTmoderate). [Web]. Available: Medvis (www.safesedationtraining.com).
    2. Egan TD, Syroid N, Agutter J, Johnson KB (10/01/2017). Safe Sedation Training for deep sedation (SSTdeep). [Web]. Available: Medvis (www.safesedationtraining.com).
    3. Egan TD (2007). Moderate sedation for non-anesthesiologists: the scientific basis of safe clinical practices. Medscape (www.medscape.com), released December 26, 2007 [Web].
    4. Egan, TD (2004). Advances in depth of anesthesia monitoring technology: Audio Digest 2004;46(23): side A. [Video]. USA: Audio Digest.
    5. Egan TD (2001). Clinical pharmacology of opioids and sedative-hypnotics. Part of an entire issue entitled "Anesthesia for the Elderly." Audio Digest 2001; 43 (17): Track 14 [Video].
    6. KSL-TV Television Documentary (1998). Awake under the knife. Television documentary produced and broadcast by KSL-TV, a Salt Lake City, Utah based National Broadcasting Company affiliate, February 26th, 1998. [Video]. Salt Lake City: National Broadcasting Company.
    7. Egan TD (1997). The New Fentanyl Congeners. Audio Digest 1997; 39(11): side A [Video].
    8. Egan TD (1997). The clinical pharmacology of the new fentanyl congeners. IARS Annual Meeting Review Course Lectures CD-ROM. International Anesthesia Research Society, Cleveland, OH [CD].

    Patent

    1. Egan, TD (2017). SST Safe Sedation Training(5338215), Applied Medical Visualizations, November 21st, 2017.
    2. Egan, TD (2017). Safe Sedation Training SST (4568924), Applied Medical Visualizations, July 15th, 2015.
    3. Egan, TD (2015). SST Sim (4590101), Applied Medical Visualizations, August 19th, 2015.

  • News & Podcasts

    News